Post-traumatic stress disorder (PTSD) is a chronic psychiatric condition that noticeably impairs quality of life, although only a limited proportion of newly diagnosed patients seek prescription drug treatment. A few modestly efficacious drugs are formally approved to treat PTSD; antidepressants and antipsychotics are the most commonly prescribed. Opportunity exists for emerging agents that offer improved efficacy and safety and tolerability. Improvements in efficacy include effects on core PTSD symptoms and on secondary disorders arising from PTSD (e.g., symptoms of anxiety disorders, proclivity toward substance abuse). Areas of improvement for safety and tolerability include effects such as weight gain and loss of libido. Commercial opportunity likely exists for a new PTSD drug that addresses these inadequacies and other areas of large unmet need (e.g., drugs that improve cognitive function or aid in complete remission).

Questions Answered

  • What are the treatment drivers and goals for PTSD?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What are the top areas of unmet need and opportunity in PTSD, and what do therapies in development for PTSD, such as Lundbeck’s Rexulti / Rxulti and Nobilis Therapeutics’ NBTX-001, have to offer?
  • What trade-offs in drug price and performance across key drug attributes are surveyed psychiatrists willing to make?

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. psychiatrists and 32 European psychiatrists fielded in March 2020

Key companies: GSK, Pfizer, Roche, Allergan, and AstraZeneca

Key drugs: prazosin, sertraline, paroxetine, diazepam, gabapentin, bupropion SR, and quetiapine

Table of contents

  • Post Traumatic Stress Disorder - Unmet Need - Detailed, Expanded Analysis (US/EU)
    • Executive Summary
      • Unmet Need - PTSD - Executive Summary - May 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for PTSD and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Psychiatrists' Prescribing Decisions in PTSD
        • Importance of Efficacy Attributes to Prescribing Decisions in PTSD: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in PTSD: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in PTSD: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in PTSD: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in PTSD: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in PTSD: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in PTSD: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in PTSD: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for PTSD: United States
        • Overall Performance of Key Therapies for PTSD: Europe
        • Mean Overall Performance of Key Therapies for PTSD: United States and Europe
        • Relative Performance of Key Therapies for PTSD Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for PTSD Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for PTSD Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for PTSD Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for PTSD Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for PTSD Across Select Convenience of Administration Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in PTSD
        • Surveyed Psychiatrists’ Satisfaction with the Performance of Key Therapies for PTSD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Psychiatrists’ Satisfaction with the Performance of Key Therapies for PTSD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in PTSD: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in PTSD: Europe
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in PTSD: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in PTSD: Europe
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in PTSD: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in PTSD: Europe
        • Key Findings: Unmet Need in PTSD and Related Indications
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need in PTSD and Related Indications: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need in PTSD and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the PTSD Market and Emerging Therapy Insights
          • Opportunity: A New Therapy with Improved Efficacy Based on a Greater Percentage of Patients with a CGI-I Score of “Very Much / Much Improved"
          • Opportunity: A New Therapy Offering Faster Time to Onset of Therapeutic Effect
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
        • Attribute Importance and Part-Worth Utilities
          • PTSD Target Product Profile: Attribute Importance
          • Mean Change from Baseline in CAPS Total Score, Placebo-Adjusted
          • % of Patients with a CGI-I Score of “Very Much / Much Improved,” Placebo-Adjusted
          • Time to Onset of Therapeutic Effect
          • % of Patients Reporting Sexual Dysfunction, Placebo-Adjusted
          • % of Patients Reporting ≥ 7% Weight Gain, Placebo-Adjusted
          • Delivery Profile
          • Price per Treated Day
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • PTSD Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • PTSD Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • PTSD Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography

    Author(s): Audreza Das, P.G. Dip.

    Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group

    She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.